Topiramate 25/50/100 mg tabs — $0 with Membership

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Seizure Disorders (Epilepsy)

• Lamotrigine
• Levetiracetam
• Lamotrigine 25/100/150/200 mg tabs
• Levetiracetam 250/500/750/1000 mg tabs

What Topiramate 25/50/100 mg tabs is approved for (FDA label)

Topiramate tablets are indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older ( 1.1 ); adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older ( 1.2 ) Preventive treatment of migraine in patients 12 years of age and older ( 1.3 ) 1.1 Monotherapy Epilepsy Topiramate tablets are indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic‑clonic seizures in patients 2 years of age and older. 1.2 Adjunctive Therapy Epilepsy Topiramate tablets are indicated as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older. 1.3 Migraine Topiramate tablets are indicated for the preventive treatment of migraine in patients 12 years of age and older.

Source: Read the full FDA label on DailyMed. Label effective date: September 4, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Topiramate 25/50/100 mg tabs (FDA label)

Topiramate Tablets, USP are available as circular, biconvex, film-coated tablets in the following strengths and colors: 50 mg yellow tablets with ‘G’ engraved on one side and ‘50’ on the other side. Tablets: 50 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 3f99b26b-79b9-4efb-aa2c-2868e1e126c8. SPL document ID: 5aae3595-129f-1ee3-e063-6294a90aaf81. Label effective date: September 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Topiramate 25/50/100 mg tabs (FDA label)

The following serious adverse reactions are discussed in more detail in other sections of the labeling: Acute Myopia and Secondary Angle Closure Glaucoma [see Warnings and Precautions ( 5.1 )] Visual Field Defects [see Warnings and Precautions ( 5.2 )] Oligohidrosis and Hyperthermia [see Warnings and Precautions ( 5.3 )] Metabolic Acidosis [see Warnings and Precautions ( 5.4 )] Suicidal Behavior and Ideation [see Warnings and Precautions ( 5.5 )] Cognitive/Neuropsychiatric Adverse Reactions [see Warnings and Precautions ( 5.6 )] Decrease of Bone Mineral Density [see Warnings and Precautions ( 5.9 )] Negative Effects on Growth (Height and Weight) [see Warnings and Precautions ( 5.10 )] Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity Reactions [see Warnings and Precautions ( 5.11 )] Serious Skin Reactions [see Warnings and Precautions ( 5.12 )] Anaphylaxis and Angioedema [see Warnings and Precautions (5.13)] Hyperammonemia and Encephalopathy (Without and With Concomitant Valproic Acid [VPA] Use) [see Warnings and Precautions ( 5.14 )] Kidney Stones [see Warnings and Precautions ( 5.15 )] Hypothermia with Concomitant Valproic Acid (VPA) Use [see Warnings and Precautions ( 5.16 )] The data described in the following sections were obtained using topiramate tablets. Epilepsy : Most common (≥10% more frequent than placebo or low-dose topiramate tablets) adverse reactions in adult and pediatric patients were: paresthesia, anorexia, weight loss, speech disorders/related speech problems, fatigue, dizziness, somnolence, nervousness, psychomotor slowing, abnormal vision and fever ( 6.1 ) Migraine: Most common (≥5% more frequent than placebo) adverse reactions in adult and pediatric patients were: paresthesia, anorexia, weight loss, difficulty with memory, taste perversion, diarrhea, hypoesthesia, nausea, abdominal pain and upper respiratory tract infection ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, the incidence of adverse reactions observed in the clinical trials of a drug cannot be directly compared to the incidence of adverse reactions in the clinical trials of another drug, and may not reflect the incidence of adverse reactions observed in practice. Monotherapy Epilepsy Adults 16 Years of Age and Older The most common adverse reactions in the controlled clinical trial (Study 1) that occurred in adults in the 400 mg/day topiramate tablets group and at an incidence higher (≥10 %) than in the 50 mg/day group were: paresthesia, weight loss and anorexia (see Table 5).

Source: FDA prescribing information (DailyMed). Set ID: 3f99b26b-79b9-4efb-aa2c-2868e1e126c8. SPL document ID: 5aae3595-129f-1ee3-e063-6294a90aaf81. Label effective date: September 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Topiramate 25/50/100 mg tabs (FDA label)

Topiramate is contraindicated in patients with a history of hypersensitivity reaction to topiramate, Topiramate tablets, or any of the inactive ingredients of Topiramate tablet. Anaphylaxis and angioedema have occurred [see Warnings and Precautions (5.13)] . History of hypersensitivity reaction to topiramate, topiramate tablets, or any of the inactive ingredients of topiramate tablet. ( 4 , 5.13 )

Source: FDA prescribing information (DailyMed). Set ID: 3f99b26b-79b9-4efb-aa2c-2868e1e126c8. SPL document ID: 5aae3595-129f-1ee3-e063-6294a90aaf81. Label effective date: September 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Topiramate 25/50/100 mg tabs (FDA label)

Acute myopia and secondary angle closure glaucoma: can lead to permanent visual loss; discontinue topiramate tablets as soon as possible ( 5.1 ) Visual field defects: consider discontinuation of topiramate tablets ( 5.2 ) Oligohidrosis and hyperthermia: monitor decreased sweating and increased body temperature, especially in pediatric patients ( 5.3 ) Metabolic acidosis: baseline and periodic measurement of serum bicarbonate is recommended; consider dose reduction or discontinuation of topiramate tablets if clinically appropriate ( 5.4 ) Suicidal behavior and ideation: antiepileptic drugs increase the risk of suicidal behavior or ideation ( 5.5 ) Cognitive/neuropsychiatric adverse reactions: use caution when operating machinery including cars; depression and mood problems may occur ( 5.6 ) Fetal Toxicity: use during pregnancy can cause major congenital malformations, including but not limited to cleft lip and/or palate, and being small for gestational age ( 5.7 ) Withdrawal of AEDs: withdraw topiramate tablets gradually ( 5.8 )

Source: FDA prescribing information (DailyMed). Set ID: 3f99b26b-79b9-4efb-aa2c-2868e1e126c8. SPL document ID: 5aae3595-129f-1ee3-e063-6294a90aaf81. Label effective date: September 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Topiramate 25/50/100 mg tabs (FDA label)

Contraceptives: decreased contraceptive efficacy and increased breakthrough bleeding, especially at doses greater than 200 mg/day ( 7.4 ) Monitor lithium levels if lithium is used with high-dose topiramate tablets ( 7.7 ) 7.1 Antiepileptic Drugs Concomitant administration of phenytoin or carbamazepine with topiramate tablets resulted in a clinically significant decrease in plasma concentrations of topiramate when compared to topiramate tablets given alone. A dosage adjustment may be needed [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.3 )]. Concomitant administration of valproic acid and topiramate tablets has been associated with hypothermia and hyperammonemia with and without encephalopathy.

Source: FDA prescribing information (DailyMed). Set ID: 3f99b26b-79b9-4efb-aa2c-2868e1e126c8. SPL document ID: 5aae3595-129f-1ee3-e063-6294a90aaf81. Label effective date: September 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.